ArticleDiscover nano2026
Antibacterial and molecular docking studies with protein stability studies into dihydropyrimidinones synthesized via silver nanoparticle catalysis: probing structure-activity relationships.
Article in Discover nano, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study reports the green synthesis of eco-friendly silver nanoparticles (AgNPs) using Aloe vera gel extract and their application as an efficient heterogeneous catalyst for the one-pot, three-component Biginelli synthesis of 3,4-dihydropyrimidin-2(1 H)-ones (DHPMs). The biosynthesized AgNPs were thoroughly characterized using UV-Vis, FTIR, XRD, SEM-EDX, and HR-TEM-SAED techniques, confirming crystalline, spherical particles. Catalyst optimization studies revealed that a low catalyst loading of 20 mg at 80 °C yielded maximum product outputs of up to 96% within an optimized reaction time of 1 h. Structural elucidation of the synthesized DHPM derivatives was completed using FTIR, ¹H NMR, ¹³C NMR, and mass spectrometry (MS). Biological screening demonstrated that the derivatives possessed significant antibacterial activity, with compound 4e exhibiting a prominent zone of inhibition (17 mm) against Salmonella typhimurium (MTCC 98). To decode the underlying mechanism, Prediction of Activity Spectra for Substances (PASS) analysis was paired with molecular docking against the Gluconate 2-dehydrogenase receptor (PDB ID: 5GNA). The PASS analysis reveals that the synthesized compounds display considerable activity as both an antieczematic agent and a Gluconate 2-dehydrogenase (acceptor) inhibitor, with a probability value (Pa) exceeding 0.07. Compound 4e demonstrated excellent binding affinity with a docking score of -8.2 kcal/mol. Furthermore, Normal Mode Analysis (NMA)-based Molecular Dynamics (MD) simulations verified the long-term stability of the protein-ligand complex, showing low main-chain deformability and a rigid eigenvalue of 4.18 × 10
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.